NAD+, NMN, and NR: A Pharmacist’s Comparison — Which Longevity Supplement Is Right for You?

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Bottom Line Up Front

NR and NMN reliably raise NAD+-related biomarkers in human blood. Whether that translates into meaningful clinical benefits — longer life, better cognition, stronger muscles, improved metabolic health — remains unresolved. Raising a biomarker is not the same as proving a clinical outcome.

The Clinical Question

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of the body, central to energy metabolism, DNA repair, and the activation of sirtuins — a family of proteins associated with longevity-related pathways in preclinical research. NAD+ levels decline with aging across multiple experimental models, but the extent and consistency of age-related NAD+ decline in humans remain less clearly established and appear to vary by tissue, population, and measurement method. Whether supplementing with NAD+ precursors meaningfully improves human health outcomes is an active area of clinical research, with biochemical target engagement established for NR and NMN but clinical health benefits remaining uncertain.

Three supplements are most commonly discussed: NAD+ (direct supplementation), NMN (nicotinamide mononucleotide), and NR (nicotinamide riboside). All three aim to raise cellular NAD+ levels through different mechanisms, with different bioavailability profiles and evidence bases. This article reviews what the human clinical research currently supports — and where it does not yet.

Understanding the NAD+ Pathway

NR and NMN are precursors that the body converts into NAD+. Their positions in the intracellular NAD+ salvage pathway:

Simplified intracellular NAD+ salvage pathway:
NR → NMN → NAD+
NMN → NAD+
This illustrates biochemical conversion, not necessarily the intact gastrointestinal absorption route of an oral supplement. The precise pathways by which orally administered NMN and NR are absorbed and metabolized in humans remain under active investigation. Other vitamin B3 precursors, including nicotinamide and nicotinic acid, can also contribute to NAD+ synthesis through separate pathways.

Direct oral NAD+ supplementation bypasses these precursor pathways but faces distinct bioavailability considerations (see below).

What the Evidence Does — and Does Not — Establish

The central scientific framework for the current evidence base:

• Established: Oral NR and NMN can raise NAD+-related biomarkers in the blood of humans.
• Preliminary: Some small RCTs show exploratory signals in metabolic function, vascular measures, and physical performance. Results across trials are heterogeneous and often endpoint-specific.
• Not established: That NR or NMN improve longevity, reverse aging, prevent diabetes, or provide broad anti-aging benefits in humans. Raising NAD+ biomarkers and actually making people healthier or live longer are different questions — and the latter remains unresolved.

NAD+ Direct Supplementation

What it is: NAD+ taken directly as an oral supplement.

Direct oral NAD+ has historically had much less human pharmacokinetic evidence than precursor approaches such as NR and NMN, in part because extracellular NAD+ undergoes substantial metabolism before cellular utilization. Emerging formulation-specific research suggests that some oral NAD+ preparations may alter blood NAD+ measures, but this evidence remains limited and cannot be generalized to all commercial NAD+ supplements. Clinical health benefits from direct oral NAD+ supplementation have not been established.

Pharmacist note: NMN and NR have more extensive human evidence for raising NAD+-related biomarkers than direct NAD+ supplements. Patients considering oral NAD+ supplements should discuss the specific product and available evidence with their pharmacist.

NMN — Nicotinamide Mononucleotide

What it is: A direct precursor to NAD+, one step away in the biosynthesis pathway. NMN is found naturally in small amounts in foods like edamame, broccoli, and avocado.

Absorption: Human studies demonstrate that oral NMN can increase circulating NAD+-related metabolites. The precise pathways by which orally administered NMN is absorbed and metabolized remain an active area of research.

Human clinical evidence — three key RCTs:

• A 2024 double-blind randomized placebo-controlled trial (PMID 38789831) in 60 older adults taking NMN 250 mg/day for 12 weeks found increased blood NAD+ metabolites. The primary outcome — a stepping test — did not show a statistically significant difference between NMN and placebo. Secondary analyses found shorter 4-meter walking time and some sleep-measure improvements, but secondary endpoints require independent confirmation. The study was industry-linked, which is relevant to evidence appraisal.
• A 2022 RCT (Igarashi et al., PMID: 35927255) in healthy older men found NMN 250 mg/day for 12 weeks increased blood NAD+ metabolites. Nominal improvements were observed in gait speed and left-hand grip performance; the authors emphasized these findings require confirmation in larger trials. No significant effect on body composition was observed.
• A 2021 RCT (Yoshino et al., PMID: 33888596) in 25 postmenopausal women with overweight and prediabetes found NMN 250 mg/day for 10 weeks improved skeletal-muscle insulin sensitivity. The trial was small and population-specific, and subsequent commentary raised concerns about baseline differences between groups. These findings do not establish NMN as a treatment for prediabetes or diabetes.

The NMN human trial literature is growing; most trials are small, short-duration, and use biomarker or surrogate endpoints rather than clinical outcomes. The pattern across trials is consistent: blood NAD+ rises reliably; clinical outcomes are mixed.

Doses studied in human trials: Vary by study; several trials have evaluated approximately 250–500 mg/day.

NR — Nicotinamide Riboside

What it is: A form of vitamin B3 and a precursor to NMN, two steps from NAD+. NR has a substantial published human clinical trial literature and consistently demonstrates biochemical NAD+ target engagement.

Human clinical evidence:

• An early human pharmacokinetic study (Trammell et al., PMID: 27721479) established that oral NR raises the blood NAD+ metabolome in a dose-dependent manner — the first published clinical pharmacokinetic study of NR. This study established bioavailability and NAD+-precursor activity, not clinical health benefits. NR was supplied by ChromaDex; several authors reported financial relationships with ChromaDex.
• A 2018 randomized crossover trial (Martens et al., PMID: 29599478; n=24) found NR 500 mg twice daily for 6 weeks increased NAD+-related metabolites and was well-tolerated. Exploratory findings suggested possible reductions in systolic blood pressure and arterial stiffness in some analyses, but the trial was small and was not designed to establish cardiovascular clinical benefit. Note: PMID 35620522 describes a planned randomized trial protocol for NR and arterial stiffness — it is a study registration, not a completed outcome study, and does not constitute evidence of cardiovascular benefit.
• A 2020 RCT (Dollerup et al., PMID: 31710095; n=40) in men with obesity and insulin resistance found NR 2,000 mg/day for 12 weeks increased NAD+-related metabolites but did not improve skeletal-muscle mitochondrial respiration, mitochondrial content, or morphology compared with placebo. These null findings illustrate that biochemical NAD+ target engagement does not necessarily translate into measurable physiological improvement.
• A randomized pilot in 20 older adults with mild cognitive impairment (Orr ME, et al., PMID: 37994989) dose-escalated NR to 1 g/day over 10 weeks. Blood NAD+ increased approximately 2.6-fold versus placebo — robust biochemical target engagement. Despite this, no significant improvement in cognitive outcomes was observed. This is a critical negative result: it directly demonstrates that substantially raising blood NAD+ does not automatically produce measurable clinical benefit, at least over the trial duration and in this population.
• A 2026 PRISMA-guided systematic review (Gallagher & Emmanuel, PMID: 41655607) of 113 studies including 33 human intervention studies (28 randomized) concluded that NR and NMN reliably show biochemical target engagement while clinical outcomes remain heterogeneous, often null or endpoint-specific; overall anti-aging and wellness effectiveness remains inconclusive. Of note, no eligible human anti-aging or wellness outcome trials for IV/IM NAD+ were identified.

Doses studied in human trials: Vary substantially by study; commonly several hundred milligrams to approximately 1,000 mg/day, with some trials evaluating higher doses.

Featured Product: Tru Niagen® Pro 500mg

Tru Niagen® Pro 500mg — Nicotinamide Riboside (30 capsules)

Per capsule: 500 mg Nicotinamide Riboside Chloride (Niagen®). Patented NR ingredient used in published human clinical studies. Manufacturer-reported product specifications: third-party tested; manufactured under cGMP standards; no artificial additives. $72.99

PharmD note: Tru Niagen® Pro contains Niagen® NR — the specific NR ingredient used in several of the published human pharmacokinetic and safety studies cited in this article. At 500 mg/day, it provides the dose range studied in multiple human trials that demonstrated blood NAD+ target engagement. We recommend it as a pharmacist-evaluated NR supplement for patients who understand the current evidence: NAD+ biomarker increases are well-supported; clinical longevity or anti-aging outcomes remain under investigation.

Head-to-Head Comparison

Evidence Grade Summary

Safety & Medication Considerations

• Diabetes medications: Small human studies have reported metabolic effects with NMN, but clinically significant hypoglycemia or established interactions with diabetes medications have not been demonstrated. Patients taking glucose-lowering medications should discuss new supplements with their pharmacist or prescriber.
• Anticoagulants: Specific clinically significant interactions between NR/NMN and warfarin or direct oral anticoagulants have not been established. Patients taking anticoagulants should nevertheless review new supplements with their pharmacist.
• Cancer treatment: NAD+ metabolism is involved in cellular energy metabolism and DNA-repair pathways. Clinical evidence establishing benefit or harm from NR/NMN during cancer therapy is insufficient; patients receiving chemotherapy or other active cancer treatment should discuss supplementation with their oncology team.
• Statins: No established clinically significant pharmacokinetic interaction between NR/NMN and statins has been identified in human studies, but both pathways involve mitochondrial and metabolic mechanisms; discuss with your pharmacist if combining.

Who May Consider Discussing NMN or NR?

• Adults interested in NAD+ precursor research who want to discuss the current human evidence with a pharmacist or healthcare professional.
• Individuals who understand that NR and NMN can raise NAD+-related biomarkers but that clinical benefits remain heterogeneous and preliminary.
• People who understand that exploratory metabolic, vascular, or physical-function findings from small studies should not be interpreted as established treatment effects.

Patients with significant medical conditions, cancer, metabolic disease, or those taking prescription medications should discuss supplementation with their treating clinician before use. NAD+ precursor supplements should not be used as a substitute for established medical treatment.

Key References

1. HUMAN STUDY Trammell SAJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PMID: 27721479.
   First published clinical pharmacokinetic study of NR; established that oral NR increases the blood NAD+ metabolome in a dose-dependent manner. Demonstrates bioavailability and NAD+-precursor activity, not clinical health benefits. NR was supplied by ChromaDex; several authors reported financial relationships with ChromaDex.
2. HUMAN RCT Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478.
   Randomized crossover trial (n=24); NR 500 mg twice daily for 6 weeks. Increased NAD+-related metabolites; well-tolerated. Exploratory findings of possible blood pressure and arterial stiffness reductions; not designed to establish cardiovascular clinical benefit. Note: PMID 35620522 is a protocol publication, not outcome data.
3. HUMAN RCT — NULL RESULT Dollerup OL, et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men. J Physiol. 2020;598(4):731–754. PMID: 31710095.
   RCT (n=40); NR 2,000 mg/day for 12 weeks increased NAD+ metabolites but did not improve skeletal-muscle mitochondrial respiration, content, or morphology. NAD+ biomarker increase ≠ physiological improvement.
4. HUMAN RCT — NULL RESULT Orr ME, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. Geroscience. 2024;46(1):665–682. PMID: 37994989.
   Randomized pilot study in 20 older adults with MCI; NR dose-escalated to 1 g/day over 10 weeks. Blood NAD+ increased approximately 2.6-fold versus placebo. No significant improvement in cognitive outcomes was demonstrated. Critical negative result: robust biochemical target engagement did not translate into measurable clinical cognitive benefit.
5. HUMAN RCT Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. PMID: 33888596.
   RCT (n=25) in postmenopausal women with overweight/prediabetes; NMN 250 mg/day for 10 weeks improved skeletal-muscle insulin sensitivity. Small, population-specific; does not establish NMN as a treatment for prediabetes or diabetes. Subsequent commentary raised concerns about baseline group differences.
6. HUMAN RCT Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022;8(1):5. PMID: 35927255.
   RCT in healthy older men; NMN 250 mg/day for 12 weeks increased blood NAD+. Nominal improvements in gait speed and grip; require confirmation in larger trials. No significant body composition change.
7. HUMAN RCT — PRIMARY ENDPOINT NS PMID 38789831 — Double-blind randomized placebo-controlled trial of NMN 250 mg/day in 60 older adults, 12 weeks.
   Primary stepping-test outcome: no statistically significant difference between NMN and placebo. Secondary findings: shorter 4-m walking time, higher blood NAD+ metabolites, some sleep-measure improvements. Industry-linked. Secondary results require independent confirmation.
8. SYSTEMATIC REVIEW Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026;116:103057. PMID: 41655607.
   113 studies total (33 human intervention studies, 28 randomized; 80 rodent studies). NR and NMN consistently demonstrate biochemical target engagement; clinical outcomes heterogeneous, often null or endpoint-specific; overall anti-aging effectiveness inconclusive. No eligible human anti-aging or wellness outcome trials identified for IV/IM NAD+.

Pharmacist's Perspective

As a PharmD, I discuss NMN and NR with patients interested in the longevity research who want to make an evidence-informed choice. The most honest summary: both NR and NMN reliably raise NAD+-related biomarkers in humans, and some small trials show interesting exploratory signals. But clinical outcomes across trials are heterogeneous and often null — the Dollerup mitochondrial RCT and the Orr MCI cognitive RCT (PMID 37994989) that raised NAD+ 2.6-fold without improving cognition are critical data points that must be part of any honest evidence review. The evidence does not yet establish that taking these supplements makes people healthier or live longer. I frame them as supplements with a reasonable emerging evidence base, not proven longevity treatments, and I always review a patient’s full medication list before recommending. Free PharmD consultation: (408) 622-8068.

Frequently Asked Questions

Q: Should I take NMN or NR?
A: Both are NAD+ precursors with published human research, but there is insufficient high-quality head-to-head evidence to conclude that one provides superior clinical health benefits. Consult our PharmD for personalized guidance.

Q: When should I take NMN or NR?
A: Human trials have used different dosing schedules, and an optimal time of day for clinical benefit has not been established. Follow the product directions or discuss timing with your pharmacist.

Q: Can I take NMN and NR together?
A: High-quality human studies evaluating combined NMN + NR supplementation are limited. Evidence has not established that combining them provides additional clinical benefit over using either precursor alone. Consult a pharmacist before combining NAD+ precursor supplements.

Q: How long does it take to see effects?
A: Blood NAD+ metabolites rise within hours of supplementation. Whether this translates to subjective or functional improvements varies by individual; most trials run 8–12 weeks before evaluating outcomes.

Q: Are NMN and NR safe?
A: Short-term human trials generally suggest that NR and NMN are well tolerated at studied doses. However, the clinical evidence base remains relatively small, and long-term safety across different populations and doses is still being established.

Related Clinical Insights Articles

• CoQ10 + PQQ: Mitochondrial Support →
• Vitamin D3 + K2: What the Research Shows →
• Resveratrol and Longevity: A Pharmacist's Evidence Review →

Reviewed by

Dai Tran, PharmD, MBA, B.S. • View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com